-
Mashup Score: 0
There is a necessity for an optimal COVID-19 vaccination strategy for vulnerable population groups, including people with autoimmune inflammatory arth…
Source: www.sciencedirect.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0People with inflammatory diseases may have impaired antibody response to COVID-19 vaccination - 3 year(s) ago
SARS-CoV-2 vaccination “essentially works” in people with immune-mediated inflammatory diseases, but humoral immune responses may be delayed and reduced, researchers report.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
This week's top story: #COVID19 #vaccination works in people with immune-mediated inflammatory diseases but humoral immune responses may be delayed and reduced. Click through to read our coverage of the findings @KorayTascilar @ARD_BMJ #RheumCovid https://t.co/ywVE30W4EX
-
-
Mashup Score: 1
Findings from the REMAP-CAP trial indicate that add-on treatment with tocilizumab or sarilumab may be beneficial for critically ill patients with COVID-19, whereas COVACTA suggests comparable outcomes with tocilizumab versus placebo in those with severe COVID-19 pneumonia.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
News: Two trials find disparate results for IL-6 inhibitors in #COVID19. Click through to read more about the REMAP-CAP and COVACTA studies @NEJM #SARSCoV2 #RheumCovid https://t.co/0XHOobphQM
-
-
Mashup Score: 1
A survey of Veterans Affairs rheumatology consortium members has given greater insight into the experiences and opinions of rheumatology providers during the COVID-19 pandemic.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
#ACR20 news: Data from a Veterans Affairs rheumatology consortium survey offers insight into the experiences and opinions of #rheumatology providers during the #COVID19 pandemic @ACR_Journals @DeptVetAffairs #RheumCovid https://t.co/uCfHhvHShj
-
-
Mashup Score: 0COVID-19 may be rare in children with rheumatic diseases - 4 year(s) ago
COVID-19 is uncommon in children with rheumatic diseases and appears to result in mild illness when it occurs, suggest data presented at the ACR Convergence 2020 virtual meeting.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
#ACR20 news: C19-GRA Patient Experience Survey data suggest #COVID19 is rare in children with #rheumatic diseases and mild when it occurs @rheum_covid #RheumCovid https://t.co/Yy0aFLVoY1
-
-
Mashup Score: 0
Cytokine inhibitor treatment for inflammatory arthritis and other immune-mediated diseases is associated with a decreased risk for SARS-CoV-2 infection, suggests research presented at the ACR Convergence 2020 virtual meeting.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
#ACR20 news: Cytokine inhibitor treatment for #RheumatoidArthritis, #spondyloarthritis & other immune-mediated diseases is associated with a reduced risk for #COVID19, report Georg Schett (@UniFAU) & colleagues #RheumCovid https://t.co/efaKOtRl63
-
-
Mashup Score: 1
Patients with rheumatic diseases from racial minority groups are more likely to experience severe outcomes if they develop COVID-19 than White patients, as is seen for the general population, US data show.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
#ACR20 news: Racial and ethnic disparities in the severity of #COVID19 outcomes exist among rheumatic patients in the same way they do in the general population, reports Milena Gianfrancesco @MilenaGianfran (@UCSFRheum) #RheumCovid @rheum_covid https://t.co/4M3nHze4k8
-
-
Mashup Score: 0‘Dearth of evidence’ to support prophylactic chloroquine, hydroxychloroquine use for COVID-19 - 4 year(s) ago
Findings from a systematic review published in the International Journal of Rheumatic Diseases confirm that there is currently insufficient evidence to support the efficacy of chloroquine or hydroxychloroquine for the prevention of COVID-19.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
News in brief: #SystematicReview highlights “dearth of evidence” to support prophylactic use of #chloroquine or #hydroxychloroquine for #COVID19, report @sanketshah07, @DurgaPrasannaM1, @jainavinash & team #coronavirus #RheumCovid https://t.co/mvNMUUpwSa
-
-
Mashup Score: 1Further evidence against hydroxychloroquine use for COVID-19 - 4 year(s) ago
The addition of hydroxychloroquine to standard care does not result in better clinical outcomes among hospitalized patients with mild-to-moderate COVID-19, say the Coalition Covid-19 Brazil I investigators.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
News in brief: Adding #hydroxychloroquine to standard care does not result in better clinical outcomes among hospitalized patients with mild-to-moderate #COVID19, report the Coalition Covid-19 Brazil I investigators @NEJM @f_g_zampieri #RheumCovid https://t.co/41XwR6zU2t
-
-
Mashup Score: 1
Stringent social distancing to prevent SARS-CoV-2 infection is associated with significantly worse physical and mental health-related quality of life among patients with rheumatic diseases, researchers report.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
News in brief: #COVID19 shielding associated with worse physical and mental health-related quality of life in #rheumatology patients, @JamesBateman (@RWT_NHS) and colleagues report in @ARD_BMJ @RheumatologyUK #RheumCovid https://t.co/Hr25981oGN
-
Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II) published in @TheLancetRheum #rheumcovid @rheum_covid https://t.co/mKucPC10y0